DIANTHUS THERAPEUTICS INC (DNTH) Fundamental Analysis & Valuation

NASDAQ:DNTH • US2528281080

65.2 USD
+3.77 (+6.14%)
At close: Mar 6, 2026
65.2 USD
0 (0%)
After Hours: 3/6/2026, 8:12:37 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This DNTH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

DNTH gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for DNTH as it has an excellent financial health rating, but there are worries on the profitability. DNTH has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. DNTH Profitability Analysis

1.1 Basic Checks

  • In the past year DNTH has reported negative net income.
  • In the past year DNTH has reported a negative cash flow from operations.
  • DNTH had negative earnings in each of the past 5 years.
  • In the past 5 years DNTH always reported negative operating cash flow.
DNTH Yearly Net Income VS EBIT VS OCF VS FCFDNTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • DNTH has a better Return On Assets (-21.88%) than 73.65% of its industry peers.
  • DNTH's Return On Equity of -23.12% is fine compared to the rest of the industry. DNTH outperforms 79.81% of its industry peers.
Industry RankSector Rank
ROA -21.88%
ROE -23.12%
ROIC N/A
ROA(3y)-33.05%
ROA(5y)-36.6%
ROE(3y)-40.68%
ROE(5y)-43.06%
ROIC(3y)N/A
ROIC(5y)N/A
DNTH Yearly ROA, ROE, ROICDNTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • DNTH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNTH Yearly Profit, Operating, Gross MarginsDNTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. DNTH Health Analysis

2.1 Basic Checks

  • DNTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for DNTH has been increased compared to 1 year ago.
  • The number of shares outstanding for DNTH has been increased compared to 5 years ago.
  • There is no outstanding debt for DNTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DNTH Yearly Shares OutstandingDNTH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
DNTH Yearly Total Debt VS Total AssetsDNTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • DNTH has an Altman-Z score of 50.35. This indicates that DNTH is financially healthy and has little risk of bankruptcy at the moment.
  • DNTH has a better Altman-Z score (50.35) than 95.96% of its industry peers.
  • There is no outstanding debt for DNTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 50.35
ROIC/WACCN/A
WACC8.77%
DNTH Yearly LT Debt VS Equity VS FCFDNTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • DNTH has a Current Ratio of 17.35. This indicates that DNTH is financially healthy and has no problem in meeting its short term obligations.
  • DNTH's Current ratio of 17.35 is amongst the best of the industry. DNTH outperforms 93.85% of its industry peers.
  • A Quick Ratio of 17.35 indicates that DNTH has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 17.35, DNTH belongs to the top of the industry, outperforming 93.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.35
Quick Ratio 17.35
DNTH Yearly Current Assets VS Current LiabilitesDNTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. DNTH Growth Analysis

3.1 Past

  • DNTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -39.20%.
  • DNTH shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -42.64%.
EPS 1Y (TTM)-39.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.08%
Revenue 1Y (TTM)-42.64%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-81.77%

3.2 Future

  • Based on estimates for the next years, DNTH will show a very negative growth in Earnings Per Share. The EPS will decrease by -18.20% on average per year.
  • DNTH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 94.34% yearly.
EPS Next Y-43.84%
EPS Next 2Y-20.93%
EPS Next 3Y-18.64%
EPS Next 5Y-18.2%
Revenue Next Year-61.55%
Revenue Next 2Y-48.85%
Revenue Next 3Y-25.37%
Revenue Next 5Y94.34%

3.3 Evolution

DNTH Yearly Revenue VS EstimatesDNTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
DNTH Yearly EPS VS EstimatesDNTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

0

4. DNTH Valuation Analysis

4.1 Price/Earnings Ratio

  • DNTH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year DNTH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNTH Price Earnings VS Forward Price EarningsDNTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNTH Per share dataDNTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • DNTH's earnings are expected to decrease with -18.64% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.93%
EPS Next 3Y-18.64%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DNTH Dividend Analysis

5.1 Amount

  • No dividends for DNTH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DNTH Fundamentals: All Metrics, Ratios and Statistics

DIANTHUS THERAPEUTICS INC

NASDAQ:DNTH (3/6/2026, 8:12:37 PM)

After market: 65.2 0 (0%)

65.2

+3.77 (+6.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)03-19
Inst Owners105%
Inst Owner Change1.89%
Ins Owners0.01%
Ins Owner Change0%
Market Cap2.80B
Revenue(TTM)3.08M
Net Income(TTM)-126.34M
Analysts87.62
Price Target76.76 (17.73%)
Short Float %19.61%
Short Ratio10.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.63%
Min EPS beat(2)-10.28%
Max EPS beat(2)1.02%
EPS beat(4)3
Avg EPS beat(4)0.68%
Min EPS beat(4)-10.28%
Max EPS beat(4)6.67%
EPS beat(8)5
Avg EPS beat(8)-0.09%
EPS beat(12)6
Avg EPS beat(12)-43.88%
EPS beat(16)8
Avg EPS beat(16)-32.73%
Revenue beat(2)0
Avg Revenue beat(2)-55.38%
Min Revenue beat(2)-78.11%
Max Revenue beat(2)-32.64%
Revenue beat(4)2
Avg Revenue beat(4)-13.77%
Min Revenue beat(4)-78.11%
Max Revenue beat(4)41.76%
Revenue beat(8)6
Avg Revenue beat(8)96.27%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.62%
PT rev (3m)16.75%
EPS NQ rev (1m)-0.8%
EPS NQ rev (3m)-0.8%
EPS NY rev (1m)-0.18%
EPS NY rev (3m)-8.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 908.31
P/FCF N/A
P/OCF N/A
P/B 5.12
P/tB 5.12
EV/EBITDA N/A
EPS(TTM)-3.48
EYN/A
EPS(NY)-3.8
Fwd EYN/A
FCF(TTM)-2.56
FCFYN/A
OCF(TTM)-2.55
OCFYN/A
SpS0.07
BVpS12.74
TBVpS12.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.88%
ROE -23.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.05%
ROA(5y)-36.6%
ROE(3y)-40.68%
ROE(5y)-43.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 65.43%
Cap/Sales 3.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.35
Quick Ratio 17.35
Altman-Z 50.35
F-Score2
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)96.54%
Cap/Depr(5y)74.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.08%
EPS Next Y-43.84%
EPS Next 2Y-20.93%
EPS Next 3Y-18.64%
EPS Next 5Y-18.2%
Revenue 1Y (TTM)-42.64%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-81.77%
Revenue Next Year-61.55%
Revenue Next 2Y-48.85%
Revenue Next 3Y-25.37%
Revenue Next 5Y94.34%
EBIT growth 1Y-69.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-162.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-162.64%
OCF growth 3YN/A
OCF growth 5YN/A

DIANTHUS THERAPEUTICS INC / DNTH FAQ

Can you provide the ChartMill fundamental rating for DIANTHUS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to DNTH.


What is the valuation status of DIANTHUS THERAPEUTICS INC (DNTH) stock?

ChartMill assigns a valuation rating of 0 / 10 to DIANTHUS THERAPEUTICS INC (DNTH). This can be considered as Overvalued.


How profitable is DIANTHUS THERAPEUTICS INC (DNTH) stock?

DIANTHUS THERAPEUTICS INC (DNTH) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for DNTH stock?

The Earnings per Share (EPS) of DIANTHUS THERAPEUTICS INC (DNTH) is expected to decline by -43.84% in the next year.